(MYGN) Myriad Genetics - Ratings and Ratios
Hereditary-Cancer, Risk, Companion, Prostate, Breast
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 65.4% |
| Value at Risk 5%th | 91.1% |
| Relative Tail Risk | -15.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -71.89 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.513 |
| Beta | 1.170 |
| Beta Downside | 1.069 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.57% |
| Mean DD | 33.84% |
| Median DD | 23.70% |
Description: MYGN Myriad Genetics October 24, 2025
Myriad Genetics (NASDAQ: MYGN) is a U.S.-based molecular diagnostics firm that commercializes DNA- and RNA-based tests across oncology, women’s health, pharmacogenomics, and mental-health indications. Its flagship offerings include the MyRisk hereditary-cancer panel, BRACAnalysis CDx and MyChoice CDx companion diagnostics for BRCA-related cancers, Prolaris and EndoPredict prognostic assays, as well as prenatal screens such as Prequel and Foresight Carrier, and the GeneSight psychotropic-medication test.
In FY 2023 the company reported revenue of roughly $1.1 billion, a 5 % year-over-year increase driven primarily by higher test volumes in its oncology and prenatal segments; the gross margin held steady near 80 %, while operating cash flow turned positive for the first time in three years, reflecting improved reimbursement capture and cost-discipline.
Key growth drivers for Myriad include the expanding market for precision oncology-projected to exceed $30 billion by 2028-accelerating adoption of companion diagnostics tied to FDA-approved targeted therapies, and demographic trends (aging population and rising cancer incidence) that boost demand for hereditary-cancer screening. Conversely, the business faces pricing pressure from emerging NGS platforms and regulatory uncertainty around coverage policies for multi-gene panels.
For a deeper, data-driven assessment of MYGN’s valuation and risk profile, you may find the analytical tools on ValueRay useful for independent research.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-400.5m TTM) > 0 and > 6% of Revenue (6% = 49.5m TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA 6.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.85% (prev 16.86%; Δ 6.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -2.20m > Net Income -400.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (93.1m) change vs 12m ago 2.42% (target <= -2.0% for YES) |
| Gross Margin 70.36% (prev 69.15%; Δ 1.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 91.22% (prev 76.17%; Δ 15.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -61.54 (EBITDA TTM -362.6m / Interest Expense TTM 6.80m) >= 6 (WARN >= 3) |
Altman Z'' -9.62
| (A) 0.27 = (Total Current Assets 344.8m - Total Current Liabilities 148.0m) / Total Assets 728.1m |
| (B) -1.53 = Retained Earnings (Balance) -1.11b / Total Assets 728.1m |
| warn (B) unusual magnitude: -1.53 — check mapping/units |
| (C) -0.46 = EBIT TTM -418.5m / Avg Total Assets 904.7m |
| (D) -3.14 = Book Value of Equity -1.11b / Total Liabilities 355.3m |
| Total Rating: -9.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.29
| 1. Piotroski 2.50pt |
| 2. FCF Yield -3.74% |
| 3. FCF Margin -3.16% |
| 4. Debt/Equity 0.57 |
| 5. Debt/Ebitda -0.18 |
| 6. ROIC - WACC (= -79.81)% |
| 7. RoE -73.93% |
| 8. Rev. Trend 88.90% |
| 9. EPS Trend 6.76% |
What is the price of MYGN shares?
Over the past week, the price has changed by -4.65%, over one month by -15.14%, over three months by -14.81% and over the past year by -51.94%.
Is MYGN a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- Strong Sell: 1
What are the forecasts/targets for the MYGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.5 | 29.9% |
| Analysts Target Price | 8.5 | 29.9% |
| ValueRay Target Price | 5.3 | -19.2% |
MYGN Fundamental Data Overview December 24, 2025
P/E Forward = 54.0541
P/S = 0.7635
P/B = 1.6377
P/EG = 1.4001
Beta = 1.815
Revenue TTM = 825.3m USD
EBIT TTM = -418.5m USD
EBITDA TTM = -362.6m USD
Long Term Debt = 119.5m USD (from longTermDebt, last quarter)
Short Term Debt = 15.8m USD (from shortTermDebt, last quarter)
Debt = 212.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 66.9m USD (from netDebt column, last quarter)
Enterprise Value = 697.0m USD (630.1m + Debt 212.3m - CCE 145.4m)
Interest Coverage Ratio = -61.54 (Ebit TTM -418.5m / Interest Expense TTM 6.80m)
FCF Yield = -3.74% (FCF TTM -26.1m / Enterprise Value 697.0m)
FCF Margin = -3.16% (FCF TTM -26.1m / Revenue TTM 825.3m)
Net Margin = -48.53% (Net Income TTM -400.5m / Revenue TTM 825.3m)
Gross Margin = 70.36% ((Revenue TTM 825.3m - Cost of Revenue TTM 244.6m) / Revenue TTM)
Gross Margin QoQ = 69.91% (prev 71.23%)
Tobins Q-Ratio = 0.96 (Enterprise Value 697.0m / Total Assets 728.1m)
Interest Expense / Debt = 1.79% (Interest Expense 3.80m / Debt 212.3m)
Taxrate = -4.58% (negative due to tax credits) (1.20m / -26.2m)
NOPAT = -437.7m (EBIT -418.5m * (1 - -4.58%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.33 (Total Current Assets 344.8m / Total Current Liabilities 148.0m)
Debt / Equity = 0.57 (Debt 212.3m / totalStockholderEquity, last quarter 372.8m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 66.9m / EBITDA -362.6m)
Debt / FCF = -2.56 (negative FCF - burning cash) (Net Debt 66.9m / FCF TTM -26.1m)
Total Stockholder Equity = 541.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.01% (Net Income -400.5m / Total Assets 728.1m)
RoE = -73.93% (Net Income TTM -400.5m / Total Stockholder Equity 541.7m)
RoCE = -63.29% (EBIT -418.5m / Capital Employed (Equity 541.7m + L.T.Debt 119.5m))
RoIC = -71.61% (negative operating profit) (NOPAT -437.7m / Invested Capital 611.2m)
WACC = 8.20% (E(630.1m)/V(842.4m) * Re(10.33%) + D(212.3m)/V(842.4m) * Rd(1.79%) * (1-Tc(-0.05)))
Discount Rate = 10.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.99%
Fair Price DCF = unknown (Cash Flow -26.1m)
EPS Correlation: 6.76 | EPS CAGR: -66.73% | SUE: -4.0 | # QB: 0
Revenue Correlation: 88.90 | Revenue CAGR: 6.79% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.00 | Chg30d=-0.003 | Revisions Net=+0 | Analysts=11
EPS next Year (2026-12-31): EPS=0.07 | Chg30d=+0.004 | Revisions Net=-2 | Growth EPS=+946.2% | Growth Revenue=+5.4%
Additional Sources for MYGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle